Rapid imaging of pulmonary metastasis from colorectal cancer with a red fluorescence probe targeting puromycin-sensitive aminopeptidase and dipeptidyl peptidase IV Authors: Kimihiko Kobayashi, Kyohhei Fujita, Ryosuke Kojima, Rumi Hino, Yasuteru Urano, Masaaki Sato Published: 2025 ABSTRACT Patients with pulmonary metastasis from primary colorectal carcinoma often undergo sublobar pulmonary metastasectomy. To prevent local cancer recurrence, it is important to ensure an appropriate resection margin. For this purpose, rapid and accurate visualization of cancer lesions by fluorescence imaging would be an effective tool to guide surgeons. Thus, the aim of this study was to find an efficient fluorescence probe for visualizing pulmonary metastases from colorectal cancer. Screening of our aminopeptidase-reactive fluorescence probe library with lysates of metastatic tissues from rectal cancer identified a specifically activated puromycin-sensitive aminopeptidase (PSA)-reactive probe. Based on this finding, we evaluated the utility of our previously reported PSA-reactive red fluorescence probe, QA-2OMeSiR, for fluorescence imaging of pulmonary metastases. QA-2OMeSiR detected pulmonary metastasis from rectal cancer with 83.3% sensitivity and 91.7% specificity (AUC = 0.875). Pulmonary metastasis from colon cancer was detected with 100% sensitivity and 88.9% specificity (AUC = 0.951). Inhibitor experiments and immunohistochemical staining confirmed that the probe targets both PSA and dipeptidyl peptidase IV (DPP-IV). Furthermore, QA-2OMeSiR rapidly visualizes the boundaries of pulmonary metastatic lesions in surgical specimens. These results suggest that QA-2OMeSiR is a promising candidate as a fluorescence probe for rapid intraoperative visualization of pulmonary metastases from colorectal cancer.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-27717-z. Introduction Pulmonary metastasectomy (PM) is the usual treatment for pulmonary metastatic cancer, and almost a half of all cases in PM arise from primary colorectal carcinoma (CRC) (Supplementary Table 1)1,2. Sublobar resections such as wedge resections are preferred where feasible in order to preserve lung function and reduce the risk of complications3. In these cases, it is important to ensure an appropriate resection margin to prevent local recurrence. In order to perform precise assessment of surgical margins, intraoperative pathological examination is occasionally used due to its diagnostic accuracy. However, this is challenged by considerations such as manpower, cost, and time to obtain a rapid diagnosis, especially regarding total-circumferential examination. When the limited number of samples from surgical margins were examined for intraoperative pathological examination, the rate of false-negative inevitably increased. Thus, there is a need for a rapid and convenient method to evaluate the entire surface of the resection margins in PM. To address this need, various activatable fluorescence probes have been developed4–7. Fluorescence of these activatable probes is initially quenched, but is activated in the presence of a cancer-specific biomarker, enabling sensitive detection of tumor tissues with extremely low background fluorescence. However, no efficient activatable fluorescence probe for human colorectal cancer pulmonary metastases has yet been reported. Our research group has developed a hydroxymethyl rhodamine green (HMRG)-based activatable fluorescence probe library for aminopeptidases and proteases, composed with 381 probes with various substrate moieties (Fig. 1a). The design concept of these probes is based on P2P1-HMRG, where P1 and P2 are various amino acids. These HMRG-based probes exist in a non-fluorescent, intramolecularly spirocyclized form, but are converted to the highly fluorescent open form upon reaction with the target enzyme8. Direct screening of this probe library with human surgical cancer specimens has already identified efficient cancer-imaging probe/biomarker enzyme pairs for various types of cancer, such as lung, esophageal, stomach, pancreas and brain tumors8–11. The identified biomarker enzymes exhibit high activities, and the probes can detect cancer tissues sensitively on an intraoperative time scale. Therefore, we aimed to apply this screening approach with human surgical specimens to discover a suitable probe/biomarker enzyme pair for imaging pulmonary metastases of colorectal cancer. Fig. 1Outcomes of screening the peptidyl-HMRG probe library with lysates of pulmonary metastasis from rectal cancer. (a) Reaction scheme of peptidyl-HMRG. When non-fluorescent peptidyl-HMRG is hydrolyzed by an aminopeptidase or a protease, it releases highly fluorescent HMRG. (b) The top 12 probe hits, ranked based on their average T2/N (CVR60 min – 0 min of tumor × T/N), and meeting the criteria of average CVR60 min – 0 min > 0.02 and average T/N > 2.0. [Peptidyl-HMRG] = 0.9 µM, [lysate] = 0.025 mg/mL. CVR, conversion rate. T/N, tumor/normal ratio. S.D., standard deviation. (c) Chemical structure of KK-HMRG. (d) Inhibitory effect of puromycin on activation of KK-HMRG. Puromycin was used as an inhibitor of PSA, and fluorescence intensity was measured after applying KK-HMRG to lysates of three specimens of pulmonary metastasis from rectal cancer. Activation of KK-HMRG was significantly suppressed by puromycin at 60 min (p = 0.0009 by Welch’s t-test). [KK-HMRG] = 1 µM, [lysate] = 0.2 mg/mL, [puromycin] = 30 µM. Outcomes of screening the peptidyl-HMRG probe library with lysates of pulmonary metastasis from rectal cancer. (a) Reaction scheme of peptidyl-HMRG. When non-fluorescent peptidyl-HMRG is hydrolyzed by an aminopeptidase or a protease, it releases highly fluorescent HMRG. (b) The top 12 probe hits, ranked based on their average T2/N (CVR60 min – 0 min of tumor × T/N), and meeting the criteria of average CVR60 min – 0 min > 0.02 and average T/N > 2.0. [Peptidyl-HMRG] = 0.9 µM, [lysate] = 0.025 mg/mL. CVR, conversion rate. T/N, tumor/normal ratio. S.D., standard deviation. (c) Chemical structure of KK-HMRG. (d) Inhibitory effect of puromycin on activation of KK-HMRG. Puromycin was used as an inhibitor of PSA, and fluorescence intensity was measured after applying KK-HMRG to lysates of three specimens of pulmonary metastasis from rectal cancer. Activation of KK-HMRG was significantly suppressed by puromycin at 60 min (p = 0.0009 by Welch’s t-test). [KK-HMRG] = 1 µM, [lysate] = 0.2 mg/mL, [puromycin] = 30 µM. Here, we show that the screening hit QA-2OMeSiR, which is activated by both puromycin-sensitive aminopeptidase (PSA) and dipeptidyl peptidase IV (DPP-IV), enables highly sensitive and specific detection of pulmonary metastases from both rectal and colon cancer. Furthermore, we confirmed that QA-2OMeSiR can rapidly visualize the boundaries of pulmonary metastatic lesions in surgical specimens. Results Screening of our fluorescence probe library with human surgical specimens of pulmonary metastasis from rectal cancer In order to find a suitable biomarker enzyme activity for pulmonary metastasis from colorectal cancer, we firstly screened our aminopeptidases and proteases-reactive fluorescence probe library with lysates of human surgically resected metastases and normal lung tissues. We used pulmonary metastasis specimens from rectal cancer of 4 different patients, as these were available at the time. When the probes react with target enzymes in lysates, they are converted to the fluorescent hydrolysis product HMRG, and the conversion rates (CVR) were calculated by dividing the fluorescence intensity of each probe by that of HMRG at the same measurement time8. For the selection of cancer imaging probes, it is desirable to select probes that exhibit a large fluorescence increase in tumor tissues with high contrast. To identify such probes, we considered two factors: CVR [60 min–0 min] (CVR60 min – 0 min) and tumor/normal fluorescence ratio (T/N). To take account of both parameters, we then calculated the CVR60 min – 0 min of tumor × T/N (T2/N), and listed the top 30 probes with the highest average values of T2/N (Supplementary Table 2). Among these probes, 12 remained after applying the criteria of average CVR60 min – 0 min > 0.02 and average T/N > 2.0 (Fig. 1b). Among the highest-performing probes (IL-HMRG, KR-HMRG, RK-HMRG and KK-HMRG), KK-HMRG exhibited the highest average value of CVR60 min – 0 min with the smallest standard deviation (S.D.) of T2/N. Since we had previously identified KK-HMRG as an effective imaging probe for lung cancer8, we considered it as a potential probe for detecting pulmonary metastases from rectal cancer. Puromycin-sensitive aminopeptidase (PSA) was identified as the target enzyme of KK-HMRG in primary lung cancer8, and to confirm that this is also the case in rectal cancer metastasis, we examined the fluorescence increase of KK-HMRG in the presence and absence of the PSA inhibitor puromycin. Puromycin significantly suppressed the fluorescence increase (Fig. 1d, Supplementary Fig. 1), as expected. Imaging-based evaluation of QA-2OMeSiR in human surgical specimens of pulmonary metastasis from colorectal cancer The above results indicated that a PSA-reactive fluorescence probe can detect pulmonary metastases from rectal cancer. Therefore, we next focused on QA-2OMeSiR, containing a 2-methyl silicon rhodamine (2OMeSiR) scaffold12, which we had previously developed as a highly sensitive PSA-reactive red fluorescence probe for primary lung cancer detection, with superior detection ability to KK-HMRG13. The fluorescence of QA-2OMeSiR is well-quenched by the combination of acceptor-excited photoinduced electron transfer (a-PeT) and absorption wavelength shifts, but cleavage of the substrate peptide by PSA results in strong fluorescence (Fig. 2a). This probe is less susceptible to interference from autofluorescence, compared to HMRG probes12,13. Interestingly, in the screening, QA-HMRG showed relatively high average T/N (2.5), but low average CVR60 min – 0 min (0.018) (Supplementary Table 3), possibly due to a relatively low affinity for the target enzyme. Thus, we next examined QA-2OMeSiR for the fluorescence detection of pulmonary metastasis specimens from rectal cancer. We applied 50 µM QA-2OMeSiR to specimens of surgically resected normal and tumor tissues from 12 patients (Supplementary Table 4). In 10 cases, the tumor tissues showed a higher time-dependent fluorescence increase than normal tissues (Fig. 2b–d). Using the fluorescence increase values at 5, 10, 20 and 30 min, we drew receiver operating characteristic (ROC) curves (Supplementary Fig. 2a). The best diagnostic performance was obtained at 10 min: the sensitivity and specificity were calculated to be 83.3% and 91.7% (AUC = 0.875), respectively (Fig. 2e). The positive predictive value (PPV), negative predictive value (NPV), and accuracy were 90.9%, 84.6%, and 87.5%, respectively (Table 1). The median T/N was 1.8 (range: 0.78–2.9). Fig. 2Outcomes of screening with pulmonary metastases from colorectal cancer. After application of 50 µM QA-2OMeSiR, images were captured by Maestro at 1, 3, 5, 10, 20 and 30 min. Fluorescence images at 640 nm were extracted. Excitation/emission = 570 nm/610 nm long pass. (a) Reaction scheme of QA-2OMeSiR. Hydrolysis of QA-2OMeSiR, which is almost non-fluorescent, by PSA or DPP-IV affords highly fluorescent 2OMeSiR. (b) Example of fluorescence imaging of surgically resected specimens of pulmonary metastasis from rectal cancer. Tumor specimens showed increased fluorescence (see panels c-e). Scale bar, 10 mm. (c) Time-dependent fluorescence increase of QA-2OMeSiR. Blue lines represent fluorescence increase of normal lung tissues. Orange lines represent fluorescence increase of tumor tissues. Error bars represent standard deviation (n = 12). (d) Dot charts of fluorescence increase at 10 min. Tumor fluorescence was significantly increased at 10 min (p = 0.00054 by Welch’s t-test). (e) Receiver operating characteristic (ROC) curves drawn with fluorescence increase values at 10 min. AUC, area under the curve. (f) Example of fluorescence imaging of surgically resected specimens of pulmonary metastasis from colon cancer. Tumor specimens showed increased fluorescence (see panels g-i). Scale bar, 10 mm. (g) Time-dependent fluorescence increase of QA-2OMeSiR. Blue lines represent fluorescence increase of normal lung tissues. Orange lines represent fluorescence increase of tumor tissues. Error bars represent standard deviation (n = 9). (h) Dot charts of fluorescence increase at 10 min. Tumor fluorescence was significantly increased at 10 min (p = 0.0051 by Welch’s t-test) (i) ROC curves drawn with fluorescence increase values at 10 min. AUC, area under the curve. Outcomes of screening with pulmonary metastases from colorectal cancer. After application of 50 µM QA-2OMeSiR, images were captured by Maestro at 1, 3, 5, 10, 20 and 30 min. Fluorescence images at 640 nm were extracted. Excitation/emission = 570 nm/610 nm long pass. (a) Reaction scheme of QA-2OMeSiR. Hydrolysis of QA-2OMeSiR, which is almost non-fluorescent, by PSA or DPP-IV affords highly fluorescent 2OMeSiR. (b) Example of fluorescence imaging of surgically resected specimens of pulmonary metastasis from rectal cancer. Tumor specimens showed increased fluorescence (see panels c-e). Scale bar, 10 mm. (c) Time-dependent fluorescence increase of QA-2OMeSiR. Blue lines represent fluorescence increase of normal lung tissues. Orange lines represent fluorescence increase of tumor tissues. Error bars represent standard deviation (n = 12). (d) Dot charts of fluorescence increase at 10 min. Tumor fluorescence was significantly increased at 10 min (p = 0.00054 by Welch’s t-test). (e) Receiver operating characteristic (ROC) curves drawn with fluorescence increase values at 10 min. AUC, area under the curve. (f) Example of fluorescence imaging of surgically resected specimens of pulmonary metastasis from colon cancer. Tumor specimens showed increased fluorescence (see panels g-i). Scale bar, 10 mm. (g) Time-dependent fluorescence increase of QA-2OMeSiR. Blue lines represent fluorescence increase of normal lung tissues. Orange lines represent fluorescence increase of tumor tissues. Error bars represent standard deviation (n = 9). (h) Dot charts of fluorescence increase at 10 min. Tumor fluorescence was significantly increased at 10 min (p = 0.0051 by Welch’s t-test) (i) ROC curves drawn with fluorescence increase values at 10 min. AUC, area under the curve. Table 1Performance parameters of QA-2OMeSiR for detection of pulmonary metastases from colorectal cancer.ProbeTargetThreshold valuePPVNPVSensitivitySpecificityAUCQA-2OMeSiRPulmonary metastases from rectal cancer0.68690.9%84.6%83.3% (95% CI: 0.52–0.98)91.7% (95% CI: 0.62-1.00)0.875 (95% CI: 0.72–1.00)Pulmonary metastases from colon cancer0.91190.0%100%100% (95% CI: 0.56-1.00)88.9% (95% CI: 0.52-1.00)0.951 (95% CI: 0.85–1.00)Sensitivity and specificity were calculated from the receiver operating characteristic curves (Fig. 2e and i). PPV, positive predictive value. NPV, negative predictive value. AUC, area under the curve. Table 1Performance parameters of QA-2OMeSiR for detection of pulmonary metastases from colorectal cancer.ProbeTargetThreshold valuePPVNPVSensitivitySpecificityAUCQA-2OMeSiRPulmonary metastases from rectal cancer0.68690.9%84.6%83.3% (95% CI: 0.52–0.98)91.7% (95% CI: 0.62-1.00)0.875 (95% CI: 0.72–1.00)Pulmonary metastases from colon cancer0.91190.0%100%100% (95% CI: 0.56-1.00)88.9% (95% CI: 0.52-1.00)0.951 (95% CI: 0.85–1.00)Sensitivity and specificity were calculated from the receiver operating characteristic curves (Fig. 2e and i). PPV, positive predictive value. NPV, negative predictive value. AUC, area under the curve. Performance parameters of QA-2OMeSiR for detection of pulmonary metastases from colorectal cancer. Sensitivity and specificity were calculated from the receiver operating characteristic curves (Fig. 2e and i). PPV, positive predictive value. NPV, negative predictive value. AUC, area under the curve. We next examined QA-2OMeSiR for fluorescence detection of pulmonary metastasis specimens from colon cancer. We applied 50 µM QA-2OMeSiR to surgically resected normal and tumor tissues from 9 patients (Supplementary Table 5). All the tumor tissues showed a higher time-dependent fluorescence increase than normal tissues (Fig. 2f–h). As in the case of rectal cancer, the best diagnostic performance was obtained at 10 min: the sensitivity and specificity of QA-2OMeSiR were calculated to be 100% and 88.9% (AUC = 0.951), respectively (Fig. 2i, Supplementary Fig. 2b). The PPV, NPV and accuracy were 90.0%, 100%, and 94.4%, respectively (Table 1). The median T/N was 2.3 (range: 1.4–3.1). These results suggested that QA-2OMeSiR is effective for rapid fluorescence detection of pulmonary metastases from colorectal cancer. Generally, normal lung tissues are reddish and contaminated with more blood than tumor tissues, which may result in fluorescence quenching. In order to confirm that the fluorescence increase reflects the target enzyme activities, we applied the 2OMeSiR fluorophore or QA-2OMeSiR to 3 samples of pulmonary metastasis from colon cancer (Supplementary Fig. 3). In the case of 2OMeSiR, the average T/N of fluorescence intensity at 10 min was 0.91 (range: 0.89–0.98). In the case of QA-2OMeSiR, the average T/N at 10 min was 2.1 (range: 1.8–2.3). These results suggest that the observed fluorescence differences between tumor and normal tissues do reflect differences of target enzyme activities. Fluorescence increase of QA-2OMeSiR in pulmonary metastasis from colorectal cancer in the presence and absence of inhibitors of target enzymes We previously identified PSA and DPP-IV as target enzymes of QA-2OMeSiR in primary lung cancer. In order to evaluate whether the observed fluorescence signals of QA-2OMeSiR are generated by these enzyme activities in colorectal cancer, we performed fluorescence imaging of specimens using QA-2OMeSiR in the presence and absence of inhibitors: puromycin for PSA and sitagliptin for DPP-IV. In the case of metastasis from colon cancer, both puromycin and sitagliptin suppressed the fluorescence increase of QA-2OMeSiR, suggesting that activities of PSA and DPP-IV mediate the fluorescence increase (Fig. 3a,b). In assays using lysates from surgical specimens, puromycin strongly suppressed the fluorescence increase, whereas sitagliptin exhibited a weak inhibition (Fig. 3c), suggesting that PSA primarily contributes to the fluorescence increase in metastases from colon cancer. Fig. 3Fluorescence imaging using QA-2OMeSiR with and without PSA and DPP-iV inhibitors (puromycin and sitagliptin, respectively). (a) Extracted fluorescence images at 640 nm of surgically resected specimens of pulmonary metastasis from colon cancer 20 min after probe application. Excitation/emission = 570 nm/610 nm long pass. [QA-2OMeSiR] = 50 µM, [puromycin] = 100 µM, [sitagliptin] = 100 µM. (b) The fluorescence intensity of QA-2OMeSiR was time-dependently decreased by each inhibitor, compared to the control, in tissue samples from panel a. (c) Examination of the inhibitory effects of puromycin and sitagliptin on activation of QA-2OMeSiR in lysates of the samples of pulmonary metastasis from colon cancer. In all three cases, puromycin strongly suppressed the fluorescence increase, whereas sitagliptin exhibited a weak inhibition. [QA-2OMeSiR] = 1 µM, [puromycin] = 30 µM, [sitagliptin] = 30 µM. (d) Extracted fluorescence images at 640 nm of the three surgically resected specimens of pulmonary metastasis from rectal cancer 30 min after probe application. Excitation/emission = 570 nm/610 nm long pass. [QA-2OMeSiR] = 50 µM, [puromycin] = 100 µM, [sitagliptin] = 100 µM. (e) The fluorescence intensity of QA-2OMeSiR in tissue samples from panel d showed little time-dependent decrease, compared to the control, in the presence of each inhibitor. (f) Examination of the inhibitory effects of puromycin and sitagliptin on activation of QA-2OMeSiR in lysates of the samples of pulmonary metastasis from rectal cancer. In all three cases, puromycin strongly suppressed the fluorescence increase, while sitagliptin weakly suppressed it. [QA-2OMeSiR] = 1 µM, [puromycin] = 30 µM, [sitagliptin] = 30 µM. Fluorescence imaging using QA-2OMeSiR with and without PSA and DPP-iV inhibitors (puromycin and sitagliptin, respectively). (a) Extracted fluorescence images at 640 nm of surgically resected specimens of pulmonary metastasis from colon cancer 20 min after probe application. Excitation/emission = 570 nm/610 nm long pass. [QA-2OMeSiR] = 50 µM, [puromycin] = 100 µM, [sitagliptin] = 100 µM. (b) The fluorescence intensity of QA-2OMeSiR was time-dependently decreased by each inhibitor, compared to the control, in tissue samples from panel a. (c) Examination of the inhibitory effects of puromycin and sitagliptin on activation of QA-2OMeSiR in lysates of the samples of pulmonary metastasis from colon cancer. In all three cases, puromycin strongly suppressed the fluorescence increase, whereas sitagliptin exhibited a weak inhibition. [QA-2OMeSiR] = 1 µM, [puromycin] = 30 µM, [sitagliptin] = 30 µM. (d) Extracted fluorescence images at 640 nm of the three surgically resected specimens of pulmonary metastasis from rectal cancer 30 min after probe application. Excitation/emission = 570 nm/610 nm long pass. [QA-2OMeSiR] = 50 µM, [puromycin] = 100 µM, [sitagliptin] = 100 µM. (e) The fluorescence intensity of QA-2OMeSiR in tissue samples from panel d showed little time-dependent decrease, compared to the control, in the presence of each inhibitor. (f) Examination of the inhibitory effects of puromycin and sitagliptin on activation of QA-2OMeSiR in lysates of the samples of pulmonary metastasis from rectal cancer. In all three cases, puromycin strongly suppressed the fluorescence increase, while sitagliptin weakly suppressed it. [QA-2OMeSiR] = 1 µM, [puromycin] = 30 µM, [sitagliptin] = 30 µM. In the case of metastasis from rectal cancer, neither of the inhibitors suppressed the fluorescence increase in tissue specimens (Fig. 3d,e), but when we evaluated these inhibitors using lysates from surgical specimens, puromycin markedly suppressed the fluorescence increase, while sitagliptin showed only weak suppression (Fig. 3f). This result suggested that PSA is primarily responsible for the fluorescence increase also in metastases from rectal cancer. We considered that this difference of inhibitor responses between tissue and lysate probably arises from a specific localization of the inhibitors in the tissues. Based on these results, the fluorescence increase of QA-2OMeSiR in metastases from colon and rectal cancer are primarily associated with PSA activity, with a smaller contribution from DPP-IV activity, although the relative contribution of each enzyme slightly varies from patient to patient. Immunohistochemical analysis of PSA and DPP-IV in pulmonary metastases from colorectal cancer To confirm the above conclusion, we evaluated the expression levels of PSA and DPP-IV in the clinical specimens by immunohistochemical (IHC) staining. Indeed, the expression levels of both PSA and DPP-IV in tumor tissues were higher than those in normal lung tissues (Fig. 4, Supplementary Figs. 4, 5). To our knowledge, these enzymes have not previously been reported as biomarker enzymes in pulmonary metastases from colorectal cancer. Fig. 4Immunohistochemical analysis of PSA and DPP-IV in pulmonary metastases from colorectal cancer. (a) Representative images of HE staining and IHC staining of PSA/DPP-IV in screened samples of pulmonary metastasis from rectal cancer. Tumor tissues overexpress PSA and DPP-IV, compared with normal lung tissues. Scale bar, 150 μm. (b) Representative images of HE staining and IHC staining of PSA/DPP-IV in screened samples of pulmonary metastasis from colon cancer. Tumor tissues express PSA and DPP-IV more strongly than normal lung tissues. Scale bar, 150 μm. Immunohistochemical analysis of PSA and DPP-IV in pulmonary metastases from colorectal cancer. (a) Representative images of HE staining and IHC staining of PSA/DPP-IV in screened samples of pulmonary metastasis from rectal cancer. Tumor tissues overexpress PSA and DPP-IV, compared with normal lung tissues. Scale bar, 150 μm. (b) Representative images of HE staining and IHC staining of PSA/DPP-IV in screened samples of pulmonary metastasis from colon cancer. Tumor tissues express PSA and DPP-IV more strongly than normal lung tissues. Scale bar, 150 μm. Application of QA-2OMeSiR for the specific demarcation of pulmonary metastasis from colorectal cancer We finally examined whether QA-2OMeSiR can visualize the boundaries of pulmonary metastatic lesions in relatively large surgically resected lung specimens. The specimens, which were expected to contain both rectal or colon cancer metastatic lesions and normal lung tissues, were incubated with a solution of QA-2OMeSiR, and fluorescence images were captured (Figs. 5a, 6a,c). Fluorescence activation was observed at specific regions corresponding to rectal and colon cancer metastases within 10–20 min. HE-staining confirmed that the highly fluorescent regions coincided with pathological cancer regions, while non-fluorescent regions were diagnosed as normal lung tissue (Figs. 5b, 6b,d). We also evaluated the expression of PSA and DPP-IV by means of IHC staining and confirmed that the pathological cancer regions exhibited higher expression of PSA and DPP-IV than the normal regions (Figs. 5b, 6b,d, Supplementary Fig. 6). These results indicated that QA-2OMeSiR is suitable for the rapid and sensitive fluorescence visualization of pulmonary metastases from colorectal cancer. Fig. 5Ability of QA-2OMeSiR to demarcate pulmonary metastasis from rectal cancer. (a) Time-dependent fluorescence images of a surgically resected specimen expected to contain both rectal cancer metastatic lesions and normal lung tissues. The entire specimen was covered with 500 µL of probe solution (final concentration 50 µM). Scale bar, 5 mm. (b) Left: White light and pseudo real color images 10 min after probe application. Fluorescence activation was observed in specific regions including #1, but not elsewhere, including #3. A clear borderline (#2) was observed. Tumor/normal ratio (T/N) of fluorescence intensity at 10 min was 2.1. Right: Images of HE staining and IHC staining of PSA/DPP-IV for each area. Highly fluorescent regions coincided with pathological cancer tissues, which were positive for PSA and DPP-IV. Insets show higher-magnification images of the tumor–normal boundaries (Supplementary Fig. 6a). Scale bar, 150 μm. Ability of QA-2OMeSiR to demarcate pulmonary metastasis from rectal cancer. (a) Time-dependent fluorescence images of a surgically resected specimen expected to contain both rectal cancer metastatic lesions and normal lung tissues. The entire specimen was covered with 500 µL of probe solution (final concentration 50 µM). Scale bar, 5 mm. (b) Left: White light and pseudo real color images 10 min after probe application. Fluorescence activation was observed in specific regions including #1, but not elsewhere, including #3. A clear borderline (#2) was observed. Tumor/normal ratio (T/N) of fluorescence intensity at 10 min was 2.1. Right: Images of HE staining and IHC staining of PSA/DPP-IV for each area. Highly fluorescent regions coincided with pathological cancer tissues, which were positive for PSA and DPP-IV. Insets show higher-magnification images of the tumor–normal boundaries (Supplementary Fig. 6a). Scale bar, 150 μm. Fig. 6Ability of QA-2OMeSiR to demarcate pulmonary metastasis from colon cancer. (a) Time-dependent fluorescence images of surgically resected specimen, expected to contain both colon cancer metastatic lesions and normal lung tissues. The entire specimen was covered with 500 µL of probe solution (final concentration 50 µM). Scale bar, 5 mm. (b) Left: White light and pseudo real color images 10 min after probe application. Fluorescence activation was observed at specific regions including #1, but not elsewhere, including #3. A clear borderline (#2) was observed. Tumor/normal ratio (T/N) of fluorescence intensity at 10 min was 2.5. Right: Images of HE staining and IHC staining of PSA/DPP-IV for each area. Highly fluorescent regions coincided with pathological cancer tissues, which were positive for PSA and DPP-IV. Insets show higher-magnification images of the tumor–normal boundaries (Supplementary Fig. 6b). Scale bar, 150 μm. (c) Time-dependent fluorescence images of a surgically resected specimen from another patient, which was also expected to contain both colon cancer metastatic lesions and normal lung tissues. The entire specimen was covered with 500 µL of probe solution (final concentration 50 µM). Scale bar, 5 mm. (d) Left: White light and pseudo real color images 10 min after probe application. Fluorescence activation was observed at specific regions including #1, but not elsewhere, including #3. A clear borderline (#2) was observed. Tumor/normal ratio (T/N) of fluorescence intensity at 10 min was 2.2. Right: Images of HE staining and IHC staining of PSA/DPP-IV for each area. Highly fluorescent regions coincided with pathological cancer tissues, which were positive for PSA and DPP-IV. Insets show higher-magnification images of the tumor–normal boundaries (Supplementary Fig. 6c). Scale bar, 150 μm. Ability of QA-2OMeSiR to demarcate pulmonary metastasis from colon cancer. (a) Time-dependent fluorescence images of surgically resected specimen, expected to contain both colon cancer metastatic lesions and normal lung tissues. The entire specimen was covered with 500 µL of probe solution (final concentration 50 µM). Scale bar, 5 mm. (b) Left: White light and pseudo real color images 10 min after probe application. Fluorescence activation was observed at specific regions including #1, but not elsewhere, including #3. A clear borderline (#2) was observed. Tumor/normal ratio (T/N) of fluorescence intensity at 10 min was 2.5. Right: Images of HE staining and IHC staining of PSA/DPP-IV for each area. Highly fluorescent regions coincided with pathological cancer tissues, which were positive for PSA and DPP-IV. Insets show higher-magnification images of the tumor–normal boundaries (Supplementary Fig. 6b). Scale bar, 150 μm. (c) Time-dependent fluorescence images of a surgically resected specimen from another patient, which was also expected to contain both colon cancer metastatic lesions and normal lung tissues. The entire specimen was covered with 500 µL of probe solution (final concentration 50 µM). Scale bar, 5 mm. (d) Left: White light and pseudo real color images 10 min after probe application. Fluorescence activation was observed at specific regions including #1, but not elsewhere, including #3. A clear borderline (#2) was observed. Tumor/normal ratio (T/N) of fluorescence intensity at 10 min was 2.2. Right: Images of HE staining and IHC staining of PSA/DPP-IV for each area. Highly fluorescent regions coincided with pathological cancer tissues, which were positive for PSA and DPP-IV. Insets show higher-magnification images of the tumor–normal boundaries (Supplementary Fig. 6c). Scale bar, 150 μm. Discussion Among common carcinomas, CRC ranks third in terms of incidence, and second in terms of mortality14. Approximately 10%-15% of all CRC patients develop pulmonary metastases15. CRC is the most common primary tumor in patients who undergo PM2, which is a well-established treatment with a 5-year survival rate of approximately 45%-54% in the case of R0 resection of pulmonary metastases from CRC16–18. In PM, sublobar resections are the most common: 67% wedge resection, 9% segmentectomy, 21% lobectomy or bilobectomy, and 3% pneumonectomy3. In sublobar resections, it is important to ensure an adequate distance between the tumor and the resection margin to prevent local recurrence. The recurrence rate at the resection margin of pulmonary metastases from CRC is reported to be 7.3% in wedge resection, and 2% in segmentectomy19. To prevent such recurrence, rapid intraoperative fluorescence visualization of tumor lesions during PM would be helpful to guide surgeons. Over the last few decades, two major types of fluorescence probes for cancer imaging have been reported: always-on and activatable4–7,20. Always-on probes accumulate at cancer sites, but constantly emit fluorescence. Thus, they have disadvantage of high background signals due to nonspecific accumulation, making it difficult to rapidly visualize tiny cancer tissues. On the other hand, activatable probes are initially almost non-fluorescent, but are activated in the presence of cancer-specific biomarkers. These probes generally achieve much lower background signals compared to always-on probes, enabling the rapid visualization of tiny cancer tissues with high T/N4. Thus, activatable probes are greatly preferred for rapid intraoperative cancer imaging. So far, several fluorescence probes for colorectal cancer metastases have been reported21–24. For example, SGM-101 is a near-infrared dye-antibody conjugate targeting carcinoembryonic antigen (CEA), but it is categorized as an always-on probe. Activatable probes targeting tumor acidity have been reported, but have so far only been examined in mouse models. In this study, based on screening of our fluorescence probe library for biomarker enzyme activities, we have established QA-2OMeSiR as the first highly sensitive activatable probe for human colorectal cancer metastases. This probe detected tumor tissues in surgically resected specimens of pulmonary metastasis from CRC with 83.3% sensitivity and 91.7% specificity for rectal cancer, and 100% sensitivity and 88.9% specificity for colon cancer. In ex vivo experiments using surgical specimens, tumor tissues were accurately detected 10 min after the topical application of QA-2OMeSiR, suggesting that the probe might be suitable for rapid intraoperative visualization of pulmonary metastasis. Since the probe can rapidly and accurately visualize the borderline between tumor and normal tissues, it is expected to be helpful for the assessment of the resected margin by visualizing even tiny tumor tissues that might not be visible to the naked eye during PM. As well as the ex vivo experiments shown in Figs. 5 and 6, this probe has potential to rapidly detect microscopic residual tumors in the remaining lung tissues in vivo by topically spraying probe solutions during PM. However, this study represents an early ex vivo proof-of-concept investigation, and further in vivo studies will be necessary to validate its feasibility and potential for intraoperative use. In this study, many specimens were cryopreserved before imaging. In a few cases, fresh tumor and adjacent normal tissues were also examined, and showed nearly comparable fluorescence intensities to those of frozen tissues, suggesting that cryopreservation did not markedly affect the target enzyme activities. In the case of metastases from rectal cancer (Fig. 2d), the fluorescence increase of two tumor samples were much lower than those of the others, and the T/N values of these two cases were less than 1.0 (#7 and #10 in Supplementary Table 4). Histological evaluation indicated that only these two cases included papillary components (average T/N = 0.82), while the other cases did not (average T/N = 2.1), suggesting that the difference of histology affected the probe activation. When these two cases were excluded, the sensitivity and specificity of QA-2OMeSiR at 10 min improved to 100% and 90% respectively (Supplementary Fig. 7). Since the histology of the primary colorectal cancer is usually evaluated prior to PM, the use of QA-2OMeSiR for surgical margin assessment can be avoided if a papillary component is identified in the primary tumor. In such cases, the margin assessment should be performed by rapid pathological examination. In the other histological subtypes, fluorescence increases with T/N > 1.5 were generally obtained (Supplementary Table 4). However, since the number of cases evaluated for each histological subtype was limited in this study, larger cohort studies will be required to clarify how histological differences affect probe activatability. This work has also established PSA and DPP-IV as new biomarker enzymes for pulmonary metastases from colorectal cancer. PSA is a cytosolic alanyl aminopeptidase25. DPP-IV is a cell-surface protease, which selectively removes the N-terminal dipeptide from peptides with alanine or proline in the second position26. In this study, we performed IHC staining and confirmed the overexpression of these enzymes in the screened tumor specimens of pulmonary metastasis tissues. In the inhibitor experiments, puromycin suppressed the fluorescence increase to a greater extent than sitagliptin. These results suggested that target enzymes of QA-2OMeSiR are both PSA and DPP-IV in pulmonary metastases from CRC, but the contribution of PSA activity is larger. However, some variability in the inhibitory effects was observed among patients. These individual differences may reflect tumor heterogeneity and represent a limitation for strategies targeting DPP-IV and PSA. To evaluate the clinical applicability, further studies involving a larger number of patients will be required. Furthermore, in the inhibitor experiments using colon cancer specimens, puromycin suppressed the fluorescence increase in both tissue samples and lysates, whereas in the case of rectal cancer, it showed much weaker suppression in tissue samples than in lysates. A likely explanation is that the uptake of puromycin differs between colon cancer and rectal cancer, possibly due to differences in the expression levels of puromycin transporters. In addition to their utility as biomarker enzymes, PSA and DPP-IV might also be available as therapeutic targets for pulmonary metastases from colorectal cancer. In this study, we were unable to evaluate PSA and DPP-IV activities or expression levels in primary colorectal cancer. However, Perez et al. reported that PSA activity in adenocarcinoma is higher than that in normal mucosa27. Thus, it is possible that PSA activity in primary CRC might be retained even after metastasis to the lungs, and if so, the same fluorescence probe would be effective to visualize both primary and metastatic lesions. However, since the background enzyme activities are likely to be different between the lung and colon, further screening is needed using specimens from each organ. Also, it remains unclear whether the enzyme activities identified in this study are necessary for the acquisition of metastatic potential. In the screening of our HMRG-based probe library with lysates of pulmonary metastasis from rectal cancer, QA-HMRG, whose substrate dipeptide is the same as that of QA-2OMeSiR, exhibited a relatively high T/N but low CVR, and was not carried forward. The reason for this may be differences in the substrate affinities of the target enzymes for the two fluorophores, HMRG and 2OMeSiR. In conclusion, QA-2OMeSiR targeting PSA and DPP-IV showed high sensitivity and specificity in the fluorescence imaging of pulmonary metastases from colorectal cancer (Table 1). We believe this probe is a promising candidate for rapid, low-cost intraoperative diagnosis of the entire surface of surgical margins, compared to conventional pathological diagnosis, and has the potential to reduce local recurrence after pulmonary metastasectomy of colorectal cancer metastases due to its high sensitivity and specificity. Methods Human surgical specimens 21 patients who underwent surgery for pulmonary metastases from CRC between October 2017 and December 2023 at the University of Tokyo were included in this study. All specimens used in this study were collected intraoperatively, and fluorescence imaging was performed with QA-2OMeSiR. Four samples were imaged in a fresh condition (rectal 1, colon 3) within a few hours after resection. Other specimens were temporarily preserved at − 80 ℃ in a freezer, and thawed on ice for imaging. Enzyme-activatable fluorescence probe We obtained QA-2OMeSiR in powder form as the trifluoroacetate salt from Goryokayaku Co., Tokyo, Japan. It was dissolved in dimethyl sulfoxide (DMSO) and stored as a 10 mM solution at − 30 °C. 2OMeSiR was synthesized according to the reported procedure12, dissolved in DMSO, and stored as 10 mM and 50 µM solutions at − 30 °C. For application to specimens, the DMSO stock solution was thawed at room temperature and diluted to a final concentration of 50 µM (QA-2OMeSiR) or 1 µM (2OMeSiR) with phosphate-buffered saline (PBS). Preparation of specimen lysates for peptidyl-HMRG probe library screening The cryopreserved tumor and normal specimens were thawed on ice at room temperature, shredded with scissors, and transferred to a Lysing Matrix D® (MP Bio Japan, Tokyo, Japan). Then, 1 mL of tissue protein extraction reagent (T-PER) (Thermo Fisher Scientific, Waltham MA) was added and the mixture was homogenized in a FastPrep®-24 (M.P. Biomedicals, Irvine, CA). After centrifugation, the supernatant was collected respectively, and protein quantification was performed using Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA). Screening of peptidyl-HMRG probe library with specimen lysates After dilution with DPBS (+), 5 µL aliquots of lysates (0.05 mg/mL) were added to a 384-well black plate (Revvity, Waltham, MA). Peptidyl-HMRG probes (0.2 mM) were diluted with DPBS (-) and 5 µL of each probe was added to the plate (final concentration 0.9 µM). Fluorescence intensity was measured at 0, 60, 120 and 180 min with a plate reader, EnVision® (PerkinElmer, Waltham, MA). Filter settings were FITC 485 (485/14 nm) for excitation and FITC 535 (535/25 nm) for emission. All subsequent EnVision® measurements were taken in the same filter settings. The probes were converted to the hydrolysis product HMRG upon reaction with their target enzymes in lysates, and the conversion rates (CVR) were calculated by dividing the fluorescence intensity of each probe by that of HMRG at the same measurement time8. Evaluation of the probes was performed based on both CVR60 min – 0 min and T/N. To take account of both parameters, CVR60 min – 0 min of tumor × T/N (T2/N) was also calculated. Examination of the inhibitory effect of puromycin on activation of KK-HMRG Lysate was prepared in the same way as above. Aliquots of 10 µL of lysate were added to a 384-well black plate (Corning, NY) after dilution with PBS (-) (final concentration 0.2 mg/mL). KK-HMRG PBS (-) solution (10 µL) was added to the plate (final concentration 1 µM). Puromycin was used as an inhibitor for PSA (final concentration 30 µM). Measurements were taken every 1 min from 0 to 60 min with an EnVision® (PerkinElmer, Waltham, MA). Filter settings were FITC 485 (485/14 nm) for excitation and FITC 535 (535/25 nm) for emission. All subsequent EnVision® measurements were taken with the same filter settings. Ex vivo fluorescence imaging of surgical specimens using QA-2OMeSiR Ex vivo fluorescence imaging was performed according to the literature procedure28. Surgically resected normal and tumor specimens were cut into pieces a few millimeters in size and these were placed separately in µ-Slide 8-Well chambers (ibidi, Germany). White-light (exposure time: 20 ms) and fluorescence (measurement wavelength: 600–850 nm) images were obtained with a Maestro in vivo imaging system (CRi Inc.). QA-2OMeSiR (50 µM PBS (-) solution, 200 µL) was added to each well, and fluorescence images were acquired at 1, 3, 5, 10, 20, and 30 min thereafter. In the case of 2OMeSiR, 1 µM PBS (-) solution (200 µL) was added. Images were consecutively captured in the wavelength range from 600 to 850 nm at 10 nm intervals. Filters were set at 570/40 nm for excitation and 610 nm long-pass for emission. Exposure time was set appropriately, depending on the fluorescence intensity. Fluorescence images at 640 nm were extracted, and fluorescence intensity was quantified by drawing regions of interest (ROIs) with the Maestro software. Fluorescence imaging using QA-2OMeSiR with and without inhibitors Fluorescence imaging of the tumor specimens was performed using QA-2OMeSiR (50 µM) in the presence or absence of inhibitors. Puromycin was used as the PSA inhibitor (final concentration 100 µM). Sitagliptin was used as the DPP-IV inhibitor (final concentration 100 µM). Sample specimens were thawed on ice at room temperature, and fluorescence imaging was performed under the same conditions as used for the screening. Examination of inhibitory effects of puromycin and sitagliptin on activation of QA-2OMeSiR Lysate was diluted with PBS(-) and 10 µL aliquots were added to a 384-well black plate (Corning, NY) (final concentration 0.2 mg/mL). QA-2OMeSiR solution diluted with PBS (-) (10 µL) was added to the plate (final concentration 1 µM). Puromycin was used as an inhibitor for PSA (final concentration 30 µM), and sitagliptin was used for DPP-IV (final concentration 30 µM). Measurements were taken every 1 min from 0 to 120 min with an EnVision® (PerkinElmer, Waltham, MA). Filter settings were BODIPY TMP FP (531/25 nm) for excitation and Cy5 (620/10 nm) for emission. All subsequent EnVision® measurements were taken with the same filter settings. Immunohistochemical staining of PSA Paraffin-embedded sections were deparaffinized, and heated in 0.5% ImmunoSaver (097-06192; FUJIFILM, Japan) for 30 min for antigen retrieval. After 20-min incubation with 3% hydrogen peroxide to block endogenous peroxidase activity, they were reacted with the primary antibody (mouse monoclonal antibody SC-390184; Santa Cruz Biotechnology, USA) in 5% skim milk for 90 min, followed by the secondary antibody (TaKaRa POD Conjugate Anti Mouse For Tissue, Japan) for 30 min at room temperature. The primary antibody was used at a dilution of 1/20. The sections were stained with a 3,3′-diaminobenzidine tetrahydrochloride (DAB) detection kit (MK210; TaKaRa), followed by counter-staining with hematoxylin. Immunohistochemical staining of DPP-IV Paraffin-embedded sections were deparaffinized, and heated in 0.5% ImmunoSaver (097-06192; FUJIFILM, Japan) for 30 min for antigen retrieval. After 20-min incubation with 3% hydrogen peroxide, the sections were reacted with the primary antibody (rabbit polyclonal antibody, HPA068778; Sigma-Aldrich, USA) in 5% skim milk for 90 min, followed by the secondary antibody (TaKaRa POD Conjugate Anti Rabbit For Tissue, Japan) for 30 min at room temperature. The primary antibody was used at a dilution of 1/50. The sections were stained with DAB a detection kit and counter-stained with hematoxylin. Fluorescence imaging of borderline lesions with QA-2OMeSiR We performed fluorescence imaging of three surgically resected pulmonary metastasis specimens from CRC containing both tumor and normal tissues. The specimens had been briefly preserved at − 80 ℃, and were thawed on ice at room temperature before imaging. Each specimen was placed on a Nunc™ EasYDish™ Dish 35 mm (Thermo Fisher Scientific, Waltham MA) and covered with 500 µL of probe solution. White light and fluorescence images were acquired at 1, 3, 5, 10, 20, and 30 min. Statistical analysis ROC curves (Fig. 2e,i, Supplementary Figs. 2a,b, 6) were prepared with statistical analysis software R 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Threshold values were determined using Youden’s index. The 95% confidence intervals (CI) for sensitivity and specificity were calculated based on Clopper-Pearson exact method, and those for the area under the curve (AUC) were calculated using DeLong’s method. The dot chart of fluorescence increase (Fig. 2d,h) was drawn with KaleidaGraph 5.0 (HULINKS, Japan). Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1